Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value - GBI Research Reports

Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value - GBI Research Reports
Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
Published Oct 03, 2011
169 pages — Published Oct 03, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value, which provides insights into metabolic disease therapeutics marled until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the major metabolic diseases including Diabetes, Obesity and Dyslipidemia. The report also provides the share of generics in global metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each three indications. The report examines the global metabolic diseases treatment usage patterns. In addition, the geographical distribution of metabolic diseases and market across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the metabolic diseases R&D product pipeline and explores the competitive landscape including major players in metabolic disorder therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in metabolic disorder therapeutics market.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global metabolic disorder therapeutics market for the three indications that includes Diabetes, Obesity and Dyslipidemia.
- Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2017 for three indications which includes diabetes, obesity and dyslipidemia
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global metabolic disorder therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global metabolic disorder market including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Novo Nordisk, Sanofi, Takeda, Eli Lilly, GlaxoSmithKline and Merck & Co. Inc.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorder therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms whi

  
Source:
Document ID
GBIHC134MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents48
  List of Tables72
  List of Figures93
Metabolic Disorders Therapeutics Market to 2017 - Introduction122
  Overview121
  GBI Research Report Guidance131
Metabolic Disorders Therapeutics Market to 2017 - Market Characterization1414
  Introduction141
  Revenue Forecast for the Metabolic Disorders Therapeutics Market to 2017151
    Revenues151
    Revenue by Country162
    Generic Share181
    Annual Cost of Treatment (ACT)191
  Treatment Usage Patterns202
    Diseased Population221
    Treatment Seeking Population231
    Diagnosed Population241
    Prescription Population251
  Drivers and Restraints of the Global Metabolic Disorders Therapeutics Market261
    Drivers for the Metabolic Disorders Therapeutics Market261
      First-in-Class Drugs in the Pipeline261
      Combination Therapies Have Started Playing a Key Role in the Dyslipidemia Market261
      High Unmet Needs Exist in the Obesity Market, and Therefore Any Drug That Can Manage to Pass Through FDA Approval will be a Blockbuster261
    Restraints for the Metabolic Disorders Therapeutics Market271
      Side Effects Affecting Prescription Sales of Diabetes Drugs271
      Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market271
Metabolic Disorders Therapeutics Market to 2017 - Geographical Landscape2824
  Revenue Analysis by Geography282
  The US301
    Revenue301
    Annual Cost of Treatment311
    Treatment Usage Pattern321
      Diseased Population331
      Treatment Seeking Population341
      Diagnosed Population351
      Prescription Population361
  Top Five Countries of Europe371
    Revenue372
    Annual Cost of Treatment391
    Treatment Usage Pattern401
      Diseased Population411
      Treatment Seeking Population421
      Diagnosed Population431
      Prescription Population441
  Japan451
    Revenue451
    Annual Cost of Treatment461
    Treatment Usage Pattern471
      Diseased Population481
      Treatment Seeking Population491
      Diagnosed Population501
      Prescription Population511
Metabolic Disorders Therapeutics Market to 2017 - Diabetes Market5214
  Introduction521
  Market Forecasts522
    Revenue by Country541
    Generic Share551
  Annual Cost of Treatment561
  Treatment Flow Algorithm571
  Treatment Usage Patterns581
    Diseased Population591
    Treatment Seeking Population601
    Diagnosed Population611
    Prescription Population621
  Major Marketed Products631
  Drivers and Restraints of the Diabetes Market641
    Drivers of the Diabetes Market641
      First-in-Class Drugs in the Pipeline641
      Increase in Prescription of Peptide Analogs641
      Sedentary Lifestyles and Obesity to Increase Diabetes Prevalence641
      Increase in Prevalence and Treatment Seeking651
    Restraints of the Diabetes Market651
      Side Effects Affecting Prescription Sales of Diabetes Drugs651
      Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market651
Metabolic Disorders Therapeutics Market to 2017 - Obesity Market6613
  Introduction661
  Market Forecasts661
    Revenue by Country671
    Generic Share681
  Annual Cost of Treatment691
  Treatment Flow Algorithm701
  Treatment Usage Patterns712
    Diseased Population731
    Treatment Seeking Population741
    Diagnosed Population751
    Prescription Population761
  Major Marketed Products771
  Drivers and Restraints of the Obesity Market771
    Drivers of the Obesity Market771
      High Unmet Needs Exist in the Obesity Market, and Therefore any Drug that can Manage to Pass through FDA Approval will be a Blockbuster771
      Rapidly Growing Obesity Population in Major Countries Driving the Growth of the Anti-Obesity Drugs Market771
    Restraints of the Obesity Market781
      Side-Effects Associated with Anti-Obesity Drugs are Very High781
      Refusal by Healthcare Authorities to Grant Reimbursement to Anti-Obesity Drugs has Impeded Growth781
      Availability of Other Non-Therapeutic Treatments such as Herbal Treatment and Weight-Loss Treatments Detrimental to the Growth of the Global Obesity Market781
Metabolic Disorders Therapeutics Market to 2017 - Dyslipidemia Market7911
  Introduction791
  Market Forecasts791
    Revenue by Country801
    Generic Share811
  Annual Cost of Treatment821
  Treatment Flow Algorithm831
  Treatment Usage Patterns841
    Diseased Population851
    Treatment Seeking Population861
    Diagnosed Population871
    Prescription Population881
  Major Marketed Products891
  Drivers and Restraints of the Dyslipidemia Market891
    Drivers of the Dyslipidemia Market891
      Combination Therapies Have Started Playing a Key Role in the Dyslipidemia Market891
    Restraints of the Dyslipidemia Market891
      The Dyslipidemia Market will Undergo a Significant Decline Due to the Patent Expiry of the Major Blockbuster Drug Lipitor891
Metabolic Disorders Therapeutics Market to 2017 - Pipeline Analysis9041
  Introduction902
  Diabetes: Research and Development Pipeline921
    Overview921
    Pipeline by Clinical Phases of Development921
      Pre-Clinical/Discovery924
      Phase I964
      Phase II1004
      Phase III1043
      NDA/Filed Molecules1071
  Obesity: Research and Development Pipeline1081
    Overview1081
    Pipeline by Clinical Phases of Development1081
      Pre-Clinical/Discovery1083
      Phase I1111
      Phase II1121
      Phase III1121
      NDA/Filed Molecules1121
  Dyslipidemia: Research and Development Pipeline1131
    Overview1131
    Pipeline by Clinical Phases of Development1141
      Pre-Clinical/Discovery1141
      Phase I1151
      Phase II1152
      Phase III1171
  Profiles of Promising Drugs in the Diabetes Market1181
    rhGAD65 (Diamyd)1181
      Introduction1181
      Mechanism of Action1181
      Clinical Trial Management1181
    DiaPep2771191
      Introduction1191
      Mechanism of Action1191
      Clinical Trial Management1191
    Otelixizumab1191
      Introduction1191
      Mechanism of Action1191
      Clinical Trial Management1201
    BMS-512148 (dapagliflozin)1201
      Introduction1201
      Mechanism of Action1201
      Clinical Trial Management1201
    D-Tagatose1211
      Introduction1211
      Mechanism of Action1211
      Clinical Trial Management1211
    JNJ-28431754 (canagliflozin)1211
      Introduction1211
      Mechanism of Action1211
      Clinical Trial Management1221
    Teplizumab1221
      Introduction1221
      Mechanism of Action1221
      Clinical Trial Management1221
    Lixisenatide1231
      Introduction1231
      Mechanism of Action1231
      Clinical Trial Management1231
  Profiles of Promising Drugs in the Obesity Market1241
    Contrave (Buropion SR + Naltrexone)1241
      Introduction1241
      Mechanism of Action1241
      Clinical Trial Management1241
    Victoza (liraglutide)1241
      Introduction1241
      Mechanism of Action1241
      Clinical Trial Management1251
    Cametor (cetilistat)1261
      Introduction1261
      Mechanism of Action1261
      Clinical Trial Management1261
  Profiles of Promising Drugs in the Dyslipidemia Market1271
    RG1658 (Dalcetrapib, JTT-705, RO4607381)1271
      Introduction1271
      Mechanism of Action1271
      Clinical Trial Management1271
    MK-0524A (Cordaptive, niacin + laropiprant)1281
      Introduction1281
      Mechanism of Action1281
      Clinical Trial Management1281
    AMR101 (LAX-101, Miraxion)1291
      Introduction1291
      Mechanism of Action1291
      Clinical Trial Management1291
    MK-0859 (anacetripib)1301
      Introduction1301
      Mechanism of Action1301
      Clinical Trial Management1301
Metabolic Disorders Therapeutics Market to 2017 - Competitive Landscape13111
  Company Profiles for Metabolic Disorders1311
    Pfizer Inc.1311
      Company Overview1311
      Business Overview1321
      SWOT Analysis1321
    Novo Nordisk1331
      Company Overview1331
      Business Overview1331
      SWOT Analysis1341
    Sanofi1341
      Company Overview1341
      Business Overview1351
      SWOT Analysis1351
    Takeda1361
      Company Overview1361
      Business Overview1361
      SWOT Analysis1361
    Eli Lilly1371
      Company Overview1371
      Business Overview1371
      SWOT Analysis1381
    GlaxoSmithKline (GSK)1381
      Company Overview1381
      Business Overview1381
      SWOT Analysis1391
    Merck &Co Inc1391
      Company Overview1391
      Business Overview1391
      SWOT Analysis1401
    Amylin Pharmaceuticals1411
      Company Overview1411
      Business Overview1411
      SWOT Analysis1411
Metabolic Disorders Therapeutics Market to 2017 - Strategic Consolidations14220
  Mergers and Acquisitions1421
    Segmentation by Indication1423
    Segmentation by Deal Value1452
    Segmentation by Geography1471
  Co-Development Deals1483
    Summary of Co-Development Deals1511
      Eli Lilly Enters into Co-Development Agreement with Boehringer Ingelheim in 20111511
      Takeda Pharmaceutical Enters into Co-Development Agreement with Kyoto University in 20111521
      The MOLLY and LINDSEY Diabetes Research Foundation Enters into an Agreement with the Diabetes Research Institute in 20111521
      Sanford-Burnham and Florida Hospital Enters into Co-Development Agreement with Takeda Pharmaceutical in 20111531
      Takeda Enters into Co-Development Agreement with Covance in 20111531
      Takeda Enters into Co-Development Agreement with Quintiles in 20111531
      Spencer Pharmaceutical Enters into Co-Development Agreement with Polyvalor in 20111541
      Otsuka Pharmaceutical Factory Enters into Research Collaboration with Living Cell Technologies for DIABECELL in 20111541

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value" Oct 03, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Metabolic-Disorders-Therapeutics-Market-to-2017-Patent-Expiry-of-Lipitor-in-2011-will-Negatively-Impact-Dyslipidemia-Market-Value-2115-275>
  
APA:
GBI Research Reports. (2011). Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value Oct 03, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Metabolic-Disorders-Therapeutics-Market-to-2017-Patent-Expiry-of-Lipitor-in-2011-will-Negatively-Impact-Dyslipidemia-Market-Value-2115-275>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.